Santosha A. Vardhana

Hematology | Oncology
530 E 74th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications

Primary Tumor Genomics and Patterns of Distant Recurrence in Resected Gastric Cancer.

Primary Tumor Genomics and Patterns of Distant Recurrence in Resected Gastric Cancer.

Journal: JAMA surgery
Published: August 05, 2026

Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications.

Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications.

Journal: Haematologica
Published: May 18, 2026

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 29, 2026

Mitochondrial ATP production promotes T cell differentiation and function by regulating chromatin accessibility.

Mitochondrial ATP production promotes T cell differentiation and function by regulating chromatin accessibility.

Journal: bioRxiv : the preprint server for biology
Published: April 03, 2026

A post-translational regulatory map of chronic antigen-driven human T cell dysfunction.

A post-translational regulatory map of chronic antigen-driven human T cell dysfunction.

Journal: bioRxiv : the preprint server for biology
Published: March 18, 2026

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Journal: Blood advances
Published: January 05, 2026

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Journal: Cancers
Published: November 27, 2025

Between ROS and a Hard Place: Telomere Damage as a Driver of T-cell Exhaustion.

Between ROS and a Hard Place: Telomere Damage as a Driver of T-cell Exhaustion.

Journal: Cancer research
Published: October 16, 2025

Smarter combos, stronger T cells in lymphoma.

Smarter combos, stronger T cells in lymphoma.

Journal: Blood
Published: October 09, 2025

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

Journal: Blood
Published: August 20, 2025

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

Journal: Blood
Published: August 20, 2025

MEK-dependent bioenergetic demand drives terminal CD8+ T cell exhaustion.

MEK-dependent bioenergetic demand drives terminal CD8+ T cell exhaustion.

Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025
Showing 1-12 of 76

Last Updated: 09/26/2026